In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?

Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/223/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/221)

Hosted on Acast. See acast.com/privacy for more information.